CMS certification 230297
Karmanos Cancer Center
4100 John R, Detroit, MI 48201
Karmanos Cancer Center has a CMS overall rating of 3 out of 5 stars. 78% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. On all 13 death, complication, infection and readmission measures CMS could compare, it is no different from the national rate.
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 397 completed surveys, 22% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | MI | US |
|---|---|---|---|
| Severe sepsis and septic shock: all recommended care given Higher is better · 18 patients | 33% | 60% | 65% |
How Karmanos Cancer Center compares with nearby hospitals
The closest hospitals of the same kind that CMS rates or surveys - the same city first, then the same county and ZIP area. Every figure is CMS's: the overall star rating, the share of patients who would definitely recommend the hospital, the median time emergency patients spent before leaving, and how many death, complication, infection and readmission measures CMS found better or worse than the national rate.
| Hospital | CMS stars | Would recommend | ER median time | Vs the nation |
|---|---|---|---|---|
| Karmanos Cancer CenterThis hospital | 3/5 | 78% | — | No different |
| Detroit (john D. Dingell) VA Medical CenterSame city | 5/5 | 70% | — | 4 better |
| Detroit Receiving HospitalSame city | 1/5 | 43% | 2 h 19 min | 2 better 1 worse |
| Harper University HospitalSame city | 1/5 | 47% | 2 h 42 min | 2 better 1 worse |
| Henry Ford Health HospitalSame city | 3/5 | 72% | 3 h 28 min | 4 better 7 worse |
| Sinai-Grace HospitalSame city | 1/5 | 35% | 2 h 23 min | 2 better 3 worse |
Hospitals differ in size and in how sick their patients are. CMS adjusts its outcome measures for that, but a star or a percentage is a starting point for questions, not a verdict. All hospitals in Detroit.
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 310 cases | Too few cases | 3.4% | 3.9% |
| Pneumonia 41 cases | Too few cases | 16.3% | 15.2% |
5 more measures had too few cases here to report.
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 1.01 likely 0.57 – 1.45 | 1 |
| Pressure ulcers (bed sores) 791 cases | No different | 0.4 per 1,000 likely 0 per 1,000 – 1.47 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 803 cases | No different | 0.2 per 1,000 likely 0 per 1,000 – 0.43 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 953 cases | No different | 0.26 per 1,000 likely 0.05 per 1,000 – 0.48 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 206 cases | No different | 3.53 per 1,000 likely 1.91 per 1,000 – 5.16 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 143 cases | No different | 1.59 per 1,000 likely 0 per 1,000 – 3.29 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 72 cases | No different | 7.58 per 1,000 likely 0 per 1,000 – 16.73 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 232 cases | No different | 4.36 per 1,000 likely 1.9 per 1,000 – 6.81 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 146 cases | No different | 6.5 per 1,000 likely 2.61 per 1,000 – 10.39 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 76 cases | No different | 2.04 per 1,000 likely 0.53 per 1,000 – 3.54 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 227 cases | No different | 2.02 per 1,000 likely 0.98 per 1,000 – 3.06 per 1,000 | 1.06 per 1,000 |
2 more measures had too few cases here to report.
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | No different | 0.78 likely 0.04 – 3.84 | 1 |
| Urinary tract infections from catheters (CAUTI) | No different | 0 | 1 |
| MRSA bloodstream infections | No different | 1.34 likely 0.42 – 3.22 | 1 |
| C. diff intestinal infections | No different | 0.98 likely 0.65 – 1.41 | 1 |
2 more measures had too few cases here to report.
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after pneumonia 79 cases | Too few cases | 16.8% | 17.3% |
| Days back in hospital after pneumonia 48 cases | Too few cases | -23.8 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 64 cases | No different | 13 per 1,000 likely 9.5 per 1,000 – 17.6 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 448 cases | No different | 9.2 per 100 likely 7.4 per 100 – 11.3 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 448 cases | No different | 5.3 per 100 likely 3.9 per 100 – 7 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 91 cases | No different | 0.9 likely 0.7 – 1.3 | — |
8 more measures had too few cases here to report.
Clinicians registered at this address
155 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 6 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Nurse Practitioner | 29 |
| Hematology & Oncology | 19 |
| Medical Oncology | 10 |
| Physician Assistant | 9 |
| Diagnostic Radiology | 6 |
| Radiation Oncology | 6 |
| Acute Care | 5 |
| Family | 5 |
| Internal Medicine | 5 |
| Surgery | 5 |
| Adult Health | 4 |
| Genetic Counselor, MS | 4 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $13.8M
- 2020 $13.3M
- 2021 $10.7M
- 2022 $5.7M
- 2023 $7.4M
- 2024 $10M
- 2025 $11.7M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Space rental and facility fees | $100,000 | 12 |
| Speaking, teaching and other services | $68,175 | 6 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Genmab U.S., Inc. | $2M | 329 |
| Regeneron Pharmaceuticals, Inc. | $1.7M | 408 |
| AstraZeneca UK Limited | $1.1M | 2 |
| Merck Sharp & Dohme LLC | $1.1M | 28 |
| Janssen Research & Development, LLC | $815,607 | 219 |
| Pfizer INC. | $641,593 | 153 |
| Celgene Corporation | $526,373 | 7 |
| AstraZeneca Pharmaceuticals LP | $363,147 | 8 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors Genmab U.S., Inc. | $1.8M |
| A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 … AstraZeneca UK Limited | $1.1M |
| A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VE… Regeneron Pharmaceuticals, Inc. · NCT06091254 | $694,389 |
| A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS PFIZER INC. | $422,965 |
| A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma Merck Sharp & Dohme LLC | $345,340 |
| A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Re… Janssen Research & Development, LLC | $328,979 |
| PHASE 1/2 STUDY OF REGN5668 (MUC16XCD28, A COSTIMULATORY BISPECIFIC) ADMINISTERED IN COMBINATION WITH CEMIPLIMAB OR REGN4018 (MUC16XCD3) Regeneron Pharmaceuticals, Inc. · NCT04590326 | $268,184 |
| A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Ad… Exelixis Inc. | $261,764 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Karmanos Cancer Center
Is Karmanos Cancer Center a good hospital?
Karmanos Cancer Center has a CMS overall rating of 3 out of 5 stars. On all 13 death, complication, infection and readmission measures CMS could compare, it is no different from the national rate. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Karmanos Cancer Center?
78% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 397 completed HCAHPS surveys.
Does Karmanos Cancer Center have an emergency room?
No. CMS does not list emergency services at Karmanos Cancer Center.
Does Karmanos Cancer Center receive money from drug and device companies?
Drug and device makers reported $11.7M in payments to Karmanos Cancer Center for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.